#### AMENDMENTS TO THE CLAIMS

# 1-18. (canceled)

19. (currently amended) A composition for induction of a induction of cytotoxic T lymphocyte response lymphocytes that lyse cancer cells upon recognition of naturally processed human telomerase reverse transcriptase peptides, comprising: at least one HLA-A2.1-restricted, human telomerase reverse transcriptase (TRT) peptide from seven to fifteen nine amino acid residues in length of a human TRT protein consisting of a sequence set forth in SEQ ID NO:23, and a physiologically acceptable carrier.

### 20. (canceled)

- 21. (previously presented) The composition of claim 19, wherein said at least one TRT peptide consists of a peptide with a sequence set forth as SEQ ID NO:1.
- 22. (previously presented) The composition of claim 19, wherein said at least one TRT peptide consists of a peptide with a sequence set forth as SEQ ID NO:2.

# 23. (canceled)

- 24. (previously presented) The composition of Claim 19, further comprising a helper peptide consisting of a peptide with a sequence set forth as SEQ ID NO:4.
- 25. (previously presented) The composition of Claim 24, wherein said helper peptide is not conjugated to said TRT peptide.

- 26. (currently amended) A composition for induction of cytotoxic T lymphocytes that lyse cancer cells upon recognition of naturally processed human telomerase reverse transcriptase peptides, comprising: at least one human telomerase reverse transcriptase (TRT) peptide from seven to fifteen nine amino acid residues in length of a human TRT protein consisting of a sequence set forth in SEQ ID NO:23, wherein said TRT peptide comprises a modification to enhance binding to HLA-A2.1.
- 27. (previously presented) The composition of claim 26, further comprising a helper peptide consisting of a peptide with a sequence set forth as SEQ ID NO:4.
- 28. (previously presented) The composition of Claim 26, wherein said modification is a tyrosine substitution.
- 29. (previously presented) The composition of Claim 28, wherein said tyrosine substitution is at position 1 of a canonical HLA-A2.1 motif.

# 30-31. (canceled)

- 32. (previously presented) The composition of Claim 28, wherein said TRT peptide is SEQ ID NO:22.
- 33. (previously presented) The composition of Claim 28, further comprising an adjuvant.
- 34. (previously presented) The composition of Claim 28, further comprising a physiologically acceptable carrier.
- 35. (previously presented) The composition of Claim 34, wherein said carrier is a mammalian cell.

- 36. (new) The composition of Claim 19, wherein said at least one TRT peptide consists of a peptide with a sequence set forth as SEQ ID NO:16.
- 37. (new) A composition for induction of cytotoxic T lymphocytes that lyse cancer cells upon recognition of naturally processed human telomerase reverse transcriptase peptides, comprising: at least one HLA-A2.1-restricted, human telomerase reverse transcriptase (TRT) peptide and a physiologically acceptable carrier, wherein said human TRT peptide is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:16.
- 38. (new) The composition of Claim 37, wherein said human TRT peptide is SEQ ID NO:1.
- 39. (new) The composition of Claim 37, wherein said human TRT peptide is SEQ ID NO:2.
- 40. (new) The composition of Claim 37, wherein said human TRT peptide is SEQ ID NO:16.
- 41. (new) A composition for induction of cytotoxic T lymphocytes that lyse cancer cells upon recognition of naturally processed human telomerase reverse transcriptase peptides, comprising: at least one human telomerase reverse transcriptase (TRT) peptide comprising a modification to enhance binding to HLA-A2.1, and a physiologically acceptable carrier, wherein said human TRT peptide is SEQ ID NO:22.